Histone deacetylases(HDACs)inhibitors are novel in cancer therapy nowadays.HDAC6-selective inhibitors exert advantageous effects due to higher selectivity and less toxicity.We explored the anti-tumor effect and the mo...Histone deacetylases(HDACs)inhibitors are novel in cancer therapy nowadays.HDAC6-selective inhibitors exert advantageous effects due to higher selectivity and less toxicity.We explored the anti-tumor effect and the molecular mechanism of cay 10603,a potent HDAC6 inhibitor in Burkitt's lymphoma cells.Our study revealed cay 10603 inhibited the proliferation of Burkitt's lymphoma cell lines,and induced caspase-dependent apoptosis.Cayl0603 inhibited the expression of CDKs and cyciins to impede cell cycle progression in both Burkitt's lymphoma cell lines.Cay 10603 also showed the additive effect with vpl 6 notably.Our data presented the promising anti-tumor effect of cay 10603 in the Burkitt's lymphoma therapy.展开更多
文摘Histone deacetylases(HDACs)inhibitors are novel in cancer therapy nowadays.HDAC6-selective inhibitors exert advantageous effects due to higher selectivity and less toxicity.We explored the anti-tumor effect and the molecular mechanism of cay 10603,a potent HDAC6 inhibitor in Burkitt's lymphoma cells.Our study revealed cay 10603 inhibited the proliferation of Burkitt's lymphoma cell lines,and induced caspase-dependent apoptosis.Cayl0603 inhibited the expression of CDKs and cyciins to impede cell cycle progression in both Burkitt's lymphoma cell lines.Cay 10603 also showed the additive effect with vpl 6 notably.Our data presented the promising anti-tumor effect of cay 10603 in the Burkitt's lymphoma therapy.
